Federal contractor · ORLANDO, FL

HESPEROS, INC

No contract obligations recorded for HESPEROS, INC in FY2026. Since FY2019: $434.4K. It also received $3.2M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
R1LSLA5YJMJ9
Other than small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 100KFY2019
  2. 159.3KFY2020
  3. 142.8KFY2021
  4. 0FY2022
  5. 0FY2023
  6. 32.2KFY2024

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for HESPEROS, INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

HESPEROS, INC received $3.2M in federal assistance in FY2026, on 5 actions (1 new awards), +29% vs FY2025. Its largest program was 93.866 · Aging Research ($1.5M).

Assistance · FY2026
$3.2M
New awards
1
Actions
5
Since FY2021
$15M

Assistance by fiscal year

  1. 3.2MFY2021
  2. 4.2MFY2022
  3. 854.8KFY2023
  4. 1MFY2024
  5. 2.5MFY2025
  6. 3.2MFY2026

By type

  1. Grants$3.2M100%

Top programs

  1. 93.866 · Aging Research$1.5M47%
  2. 93.855 · Allergy and Infectious Diseases Research$1M31%
  3. 93.350 · National Center for Advancing Translational Sciences$720.9K22%

Awarding agencies

  1. National Institutes of Health$3.2M100%
    Department of Health and Human Services

Largest awards

  1. MODULATORY ROLE OF BLOOD-BRAIN-BARRIER AND ENZYMATIC ACTIVITY IN AN INNOVATIVE HUMAN MODEL OF CHOLINERGIC DRUG INDUCED DEMENTIA - PROJECT…$5M
    93.866 · Aging Research· National Institutes of Health· Project grant· Aug 10, 2021 – Aug 19, 2026· R44AG071386
  2. HUMAN NEUROMUSCULARJUNCTION PLATFORM TO EVALUATE BOTULINUM TOXIN POTENCY$2M
    93.350 · National Center for Advancing Translational Sciences· National Institutes of Health· Cooperative agreement· Apr 23, 2024 – Aug 26, 2026· U44TR004811
  3. EXPANDED IMPLEMENTATION OF A HUMAN-BASED MALARIA-ON-A-CHIP PHENOTYPIC DISEASE MODEL FOR THE EVALUATION OF THERAPEUTIC EFFICACY AND…$1M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 28, 2026 – Aug 28, 2026· R44AI197758
  4. HUMAN NEUROMUSCULAR JUNCTION PLATFORM TO EVALUATE BOTULINUM TOXIN POTENCY - PROJECT SUMMARY: BOTULINUM NEUROTOXIN (BONT) HAS BEEN PROVEN…$720.9K
    93.350 · National Center for Advancing Translational Sciences· National Institutes of Health· Project grant· Jul 21, 2026 – Jul 21, 2026· R44TR004811

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.